Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr Kim on Selecting Between Frontline Immunotherapy-Based Regimens in HCC

January 12th 2024

Richard Kim, MD, discusses selecting between frontline immunotherapy-based regimens in patients with hepatocellular carcinoma.

Camrelizumab With Rivoceranib Elicits PFS and OS Benefit Over Sorafenib in Unresectable HCC

January 12th 2024

Amit Mahipal, MD, discusses clinical outcomes with camrelizumab plus rivoceranib in unresectable HCC, based on data from the phase 3 CARES-310 trial.

NALIRIFOX Prolongs Survival With a Tolerable Safety Profile in mPDAC

January 11th 2024

Davide Melisi, MD, PhD, discusses the potential of NALIRIFOX as a new first-line standard for patients with metastatic pancreatic ductal adenocarcinoma.

FDA Accepts Filing of Abbreviated NDA for Generic Lutathera in GEP-NETs

January 11th 2024

The FDA has accepted the filing of an ANDA for Lutetium Lu 177 Dotatate indicated for patients with gastroenteropancreatic neuroendocrine tumors.

The Role of Biomarker Testing in Diagnosing Cholangiocarcinoma

January 10th 2024

Experts in treating cholangiocarcinoma share insights on when biomarker testing is needed and which biomarkers to test for.

Clinical Presentations of Patients With Cholangiocarcinoma

January 10th 2024

Key opinion leaders illustrate how patients with intrahepatic cholangiocarcinoma present in a clinical setting.

Risk Factors Leading to Various Liver Cancers

January 10th 2024

The intricate web of risk factors influencing diverse forms of liver cancers are explored.

Dr In on the Importance of Early Cancer Prevention Strategies in Gastric Cancer

January 9th 2024

Haejin In, MD, MPH, MBA, FACS, FSSO, discusses the importance of identifying individuals at high risk for developing gastric cancer.

FDA Issues CRL to Zolbetuximab for Advanced HER2–, CLDN18.2+ Gastric/GEJ Cancer

January 9th 2024

The FDA has issued a CRL to the zolbetuximab BLA for patients with HER2- gastric or GEJ junction adenocarcinoma whose tumors are Claudin18.2 positive.

NMPA Approval Sought for Frontline Cadonilimab Plus Chemo in Gastric or GEJ Adenocarcinoma

January 8th 2024

China’s NMPA has accepted the sNDA seeking the approval of cadonilimab plus chemotherapy for use in select patients with gastric or GEJ adenocarcinomas.

Neoadjuvant SBRT Plus Cemiplimab Results in Pathologic Responses in Resectable HCC

January 5th 2024

Significant tumor necrosis greater than 70% occurred in 3 patients with resectable hepatocellular carcinoma following neoadjuvant treatment with low-dose stereotactic body radiation therapy and cemiplimab-rwlc and adjuvant cemiplimab.

The Power of Patient Connection

January 4th 2024

Patient care begins with the patient, and Deb Schrag, MD, MPH, has spent her career keeping them the main focus of improving oncologic outcomes.

Dr Kim on a Case Study of a Patient With HCC

January 3rd 2024

Richard Kim, MD, discusses a case study of a patient who presented with hepatocellular carcinoma, detailing the steps that were taken upon diagnosis.

FDA Grants Fast Track Status to Aglatimagene Besadenovec Plus Valacyclovir for Pancreatic Cancer

January 2nd 2024

The FDA has granted fast track designation to aglatimagene besadenovec plus valacyclovir for use as a potential therapeutic option in patients with pancreatic ductal adenocarcinoma.

Sugemalimab Plus Chemo Receives Approval in China for Esophageal Squamous Cell Carcinoma

January 2nd 2024

The National Medical Products Administration of China has approved sugemalimab paired with fluorouracil and platinum-based chemotherapy for use in the frontline treatment of patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma.

Future Directions in the Management of Hepatocellular Carcinoma

January 2nd 2024

To close, Dr. Saeed and Dr. Singal share their excitement for the future landscape, emerging agents and treatment strategies for patients with HCC.

Revolutionizing GI Oncology Around the Globe

December 28th 2023

Eileen M. O’Reilly, MD, traveled a serendipitous journey from Ireland to the United States, where she has made her mark on transforming gastrointestinal cancer treatment.

What Fellows Need to Know: Key Takeaways From ESMO 2023

December 26th 2023

The 2023 ESMO Congress took place October 20 to 24 in Madrid, Spain, with global perspectives on groundbreaking data. We break down some of the key highlights from the annual meeting that oncology fellows should absorb, and apply to practice, as soon as possible.

Additional Data Updates from AASLD 2023

December 26th 2023

Drs Saeed and Singal discuss additional data presented at AASLD 2023 related to frontline systemic therapies and emerging combinations in unresectable HCC.

Real-World Data and Impact on Treatment Selection in uHCC

December 26th 2023

Expert oncologists review real-world data and discuss the impact on treatment selection in uHCC.